source
- EU regulators back Minoryx’s ALD therapy while rejecting Zevra’s rare-disease drugThe EU Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Minoryx Therapeutics' drug for adrenoleukodystrophy, marking a significant regulatory step after previous c…
- Summit Therapeutics faces under a year of cash runway as FDA decision on ivonescimab loomsSummit Therapeutics reported that its cash and short-term investments total just over $690 million, which the company says is insufficient to fund operations for a full year. The biotech’s lead ca…